Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zhengyi Cheng

Internal Medicine Fairfax, VA Medical Doctor

NPI 1316963085 CMS profile 331959

8318 Arlington Blvd, Ste 302, Fairfax, VA 22031

Open in the dashboard

General payments

$5,180

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zhengyi Cheng of Fairfax, VA is reported in the CMS Open Payments database as having received $5,180 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $821 39
2024 General $1,164 60
2023 General $805 45
2022 General $764 42
2021 General $698 39
2020 General $501 30
2019 General $428 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zhengyi Cheng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Zhengyi Cheng were reported at $821. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Zhengyi Cheng Internal Medicine median Middle half National median
2019 $428 $159 $48–$570 $163
2020 $501 $119 $33–$402 $114
2021 $698 $135 $37–$521 $132
2022 $764 $141 $42–$496 $149
2023 $805 $149 $45–$519 $160
2024 $1,164 $154 $47–$537 $164
2025 $821 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $1,109 69 payments
  2. AstraZeneca Pharmaceuticals LP $777 41 payments
  3. Amgen Inc. $544 28 payments
  4. Novo Nordisk Inc $528 29 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $387 17 payments
  6. Janssen Pharmaceuticals, Inc $276 13 payments
  7. Amarin Pharma Inc. $264 16 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $223 12 payments
  9. Lilly USA, LLC $204 10 payments
  10. GlaxoSmithKline, LLC. $199 11 payments
  11. Other $670 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,144 281 payments
  2. Education $36 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $528 29 payments
  2. RYBELSUS $528 29 payments
  3. FARXIGA $350 19 payments
  4. BREZTRI $326 14 payments
  5. XARELTO $276 13 payments
  6. EVENITY $259 13 payments
  7. Kerendia $223 12 payments
  8. Vascepa $218 13 payments
  9. JARDIANCE $217 10 payments
  10. TRELEGY ELLIPTA $199 11 payments
  11. Other $2,522 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

10,778

Median for Internal Medicine: 777

Drug cost

$1,289,588

Median for Internal Medicine: $73,373

Branded share of claims

18.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 304 $178,959
Farxiga Dapagliflozin Propanediol Brand 117 $173,230
Vemlidy Tenofovir Alafenamide Brand 79 $138,055
Jardiance Empagliflozin Brand 63 $108,559
Linzess Linaclotide Brand 68 $101,837
Prolia Denosumab Brand 54 $93,734
Eliquis Apixaban Brand 52 $90,009
Xarelto Rivaroxaban Brand 35 $57,826
Ozempic Semaglutide Brand 24 $45,581
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $44,338

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$232,002

Of which drugs: $3,405

Medicare patients

404

Average age 77

Services billed

2,782

229 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Diabetes 34%
Arthritis 22%
Ischemic heart disease 15%
Osteoporosis 12%
Alzheimer's or dementia 9%
Cancer 8%
Chronic kidney disease 7%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 79 79 $1,692

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $83
  • Boehringer Ingelheim Pharmaceuticals, Inc. $68
$151 63 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $109
$109 15 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $82
$82 — —
RYBELSUS
  • Novo Nordisk Inc $60
$60 — —
Ozempic
  • Novo Nordisk Inc $60
$60 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record